Tag: Clinical Trial
Avelumab Fails to Extend PFS in Ovarian Cancer
January 2, 2019 5:00 pmThe JAVELIN Ovarian 100 study has been terminated based on the finding, reported as part… Read more
Merck, Pfizer’s Bavencio Misses Ovarian Cancer Trial Endpoints
November 26, 2018 7:45 pmBy Selina McKee
A late-stage study testing Merck KGaA and Pfizer’s PD-L1 antibody Bavencio has failed to meet its primary endpoints in patients with certain forms of ovarian cancer.
The drug was being tested as monotherapy and in combination with … Read more
Ovarian Cancer ‘Breakthrough’ Drug Prevents Disease Returning for Years
October 22, 2018 4:35 pmBy
A new ovarian cancer treatment dramatically reduces the chances of the disease returning, a study has shown.
Doctors have hailed the results of a “breakthrough” trial which they say opens the possibility that many more women suffering … Read more
New Blood Test Could Spare Cancer Patients From Unnecessary Chemotherapy
October 17, 2018 10:02 pmCancer patients could be spared unnecessary chemotherapy – and its side effects – by a new blood test that is in clinical trials at more than 40 hospitals in Australia and New Zealand.
The trials, led by Melbourne researchers, are … Read more
Early Clinical Trials Showing Promise for New Kind of Cancer Vaccine
September 30, 2018 3:14 pmBy Rich Haridy
Promising early results are in from a phase 1 clinical trial into the safety and efficacy of a new cancer vaccine. The new treatment is designed to stimulate the immune system into attacking certain cancers known to … Read more
CTLA4 Targeted Therapy Plus PD-1 Targeted Therapy Could Benefit Women With Ovarian Cancer
September 19, 2018 12:22 amAn analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival … Read more
New Developments in Ovarian Cancer Treatment Are Showing Promise
September 14, 2018 4:29 pmCancer is never an easy foe, but some types are more stubborn than others. Ovarian cancer is one of the hardest to treat.
But there are signs of progress. Several recent studies have used new combination treatment strategies, including a … Read more
Drug Combination Gives ‘Exciting’ Results in Ovarian and Lung Cancer in Early Trial
August 24, 2018 1:58 amCombining a new targeted cancer drug with chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.
The combination of targeted drug vistusertib along with paclitaxel chemotherapy … Read more
Tumor Treating Fields Plus Paclitaxel Appears Safe, Effective in Recurrent Ovarian Cancer
August 16, 2018 12:57 amQuality of Life Maintained With Niraparib for Ovarian Cancer
August 1, 2018 9:19 pmby Madeline Marr
The use of niraparib in women receiving treatment for platinum-sensitive recurrent ovarian cancer did not adversely affect quality of life (QoL), according to a study published in The Lancet Oncology.
An international team of researchers led … Read more
Treating Ovarian Cancers by Targeting Mutations
July 31, 2018 11:22 pmNew research has shown that ovarian cancer patients with a tumor mutation in the BRAF gene respond exceptionally well to treatment with targeted drugs, known as BRAF inhibitors.
BRAF inhibitors block the activity of mutated BRAF gene. They are currently … Read more
Can a personalized cancer vaccine effectively treat ovarian cancer?
July 6, 2018 9:12 pmFor most advanced ovarian cancers, the current treatment is a combination of surgery and chemotherapy. Initially, patient response to this treatment
… Read moreASCO 2018: Dendritic Cell Vaccine
June 20, 2018 5:46 pmDendritic cell vaccine improved progression-free survival when administered sequentially after chemotherapy. The vaccine provides a promising maintenance treatment option to delay progression of epithelial ovarian carcinoma.
This outcome of an interim analysis of a phase II, open-label, randomized, multicenter trial … Read more
Bevacizumab Rechallenge Benefit in Recurrent Ovarian Cancer?
June 19, 2018 5:43 pmA new study suggests that a rechallenge with bevacizumab in combination with platinum-based chemotherapy may prolong progression-free survival (PFS) in patients with recurrent ovarian cancer (ROC) who already received this agent during first-line treatment. The study was presented by Italian … Read more
FDA Approves Bevacizumab Plus Chemotherapy in Advanced OC
June 14, 2018 7:32 pmToday, the U.S. Food and Drug Administration (FDA) approved bevacizumab (Avastin) in combination with chemotherapy (carboplatin and paclitaxel) followed by bevacizumab as a single agent for the treatment of women with advanced (stage III or IV) ovarian cancer following initial … Read more
Olaparib Plus Vistusertib Promising in Early Trial
June 8, 2018 9:48 pmThe combination of the PARP inhibitor olaparib with an mTORC1/2 inhibitor known as vistusertib was tolerable and had promising activity across endometrial, ovarian, and triple-negative breast cancers, according to a phase I trial. Results of the trial (abstract 5504… Read more
Pembrolizumab Monotherapy Shows Activity in Advanced Recurrent OC
June 7, 2018 9:52 pmPembrolizumab monotherapy is associated with antitumor activity in patients with advanced recurrent ovarian cancer, interim results from the phase 2 KEYNOTE-100 study suggest.
Notably, objective response rates among study subjects increased in tandem with increased programmed death-ligand 1 (PD-L1) expression, … Read more
‘Personalized’ Ovarian CA Vaccine May Prolong Survival
April 16, 2018 9:42 pmA novel cancer vaccine made from autologous whole-tumor and dendritic cells significantly improved survival in women with recurrent advanced epithelial ovarian cancer (EOC), given alone or in combination with standard immunomodulatory therapy, researchers found.
An international pilot study in 25 … Read more
New Immunotherapy Shows Promise Against Ovarian Cancer
April 10, 2018 8:57 pmOvarian cancer can be tough to beat, particularly if it returns after initial treatment, but new research offers a glimmer of hope.
One study found that a new targeted “immunotherapy” to treat ovarian cancer that has come back looked promising … Read more